JP6313415B2 - Ｉｄｏ阻害剤 - Google Patents
Ｉｄｏ阻害剤 Download PDFInfo
- Publication number
- JP6313415B2 JP6313415B2 JP2016501372A JP2016501372A JP6313415B2 JP 6313415 B2 JP6313415 B2 JP 6313415B2 JP 2016501372 A JP2016501372 A JP 2016501372A JP 2016501372 A JP2016501372 A JP 2016501372A JP 6313415 B2 JP6313415 B2 JP 6313415B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- mmol
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XUKQPGXMFWVVAJ-UHFFFAOYSA-N CC(C)CN(CC(C)C)c(ccc(C(C)CC(O)=O)c1)c1NC(Nc1n[o]c(C)c1)=O Chemical compound CC(C)CN(CC(C)C)c(ccc(C(C)CC(O)=O)c1)c1NC(Nc1n[o]c(C)c1)=O XUKQPGXMFWVVAJ-UHFFFAOYSA-N 0.000 description 1
- HNEJQDJQBPNEJR-KRWDZBQOSA-N CC(C)CN(CC(C)C)c(ccc([C@@H](C)CC(O)=O)c1)c1NC(Nc1cnc(C)nc1)=O Chemical compound CC(C)CN(CC(C)C)c(ccc([C@@H](C)CC(O)=O)c1)c1NC(Nc1cnc(C)nc1)=O HNEJQDJQBPNEJR-KRWDZBQOSA-N 0.000 description 1
- ATQRSWOZWFTTRW-UHFFFAOYSA-N CC(CC(O)=O)c(cc1)cc(NC(Nc2ccc(C)cc2)=O)c1OCCCc1ccccc1 Chemical compound CC(CC(O)=O)c(cc1)cc(NC(Nc2ccc(C)cc2)=O)c1OCCCc1ccccc1 ATQRSWOZWFTTRW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787939P | 2013-03-15 | 2013-03-15 | |
| US61/787,939 | 2013-03-15 | ||
| PCT/US2014/023877 WO2014150646A1 (en) | 2013-03-15 | 2014-03-12 | Ido inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518324A JP2016518324A (ja) | 2016-06-23 |
| JP2016518324A5 JP2016518324A5 (enExample) | 2017-03-02 |
| JP6313415B2 true JP6313415B2 (ja) | 2018-04-18 |
Family
ID=50391513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501372A Active JP6313415B2 (ja) | 2013-03-15 | 2014-03-12 | Ｉｄｏ阻害剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9624188B2 (enExample) |
| EP (1) | EP2970114B1 (enExample) |
| JP (1) | JP6313415B2 (enExample) |
| KR (1) | KR20150129010A (enExample) |
| CN (1) | CN105324362B (enExample) |
| AU (1) | AU2014235816B2 (enExample) |
| BR (1) | BR112015022462A8 (enExample) |
| CA (1) | CA2907178A1 (enExample) |
| EA (1) | EA028424B1 (enExample) |
| ES (1) | ES2733546T3 (enExample) |
| HK (1) | HK1220442A1 (enExample) |
| IL (1) | IL241321A0 (enExample) |
| MA (1) | MA38483A1 (enExample) |
| MX (1) | MX2015012056A (enExample) |
| PE (1) | PE20151594A1 (enExample) |
| PH (1) | PH12015502028A1 (enExample) |
| SG (1) | SG11201506920QA (enExample) |
| WO (1) | WO2014150646A1 (enExample) |
| ZA (1) | ZA201506796B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| HRP20180971T1 (hr) * | 2013-03-15 | 2018-08-10 | Bristol-Myers Squibb Company | Inhibitori indolamin 2,3-dioksigenaze (ido) |
| CN105473550B (zh) | 2013-07-01 | 2019-02-15 | 百时美施贵宝公司 | Ido抑制剂 |
| CA2917964A1 (en) * | 2013-07-11 | 2015-01-15 | Bristol-Myers Squibb Company | Ido inhibitors |
| SG10202001019TA (en) | 2015-03-23 | 2020-04-29 | Jounce Therapeutics Inc | Antibodies to icos |
| CA2981584A1 (en) * | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
| CN107922353A (zh) * | 2015-06-26 | 2018-04-17 | 百时美施贵宝公司 | Ido抑制剂 |
| BR112018000903A2 (pt) | 2015-07-16 | 2018-09-11 | Biokine Therapeutics Ltd. | composições e métodos para o tratamento de câncer |
| EP3324958B1 (en) | 2015-07-24 | 2021-07-28 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
| KR20180054827A (ko) * | 2015-09-24 | 2018-05-24 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인돌아민 2,3-디옥시게나제의 조절제 |
| JP6971239B2 (ja) * | 2015-10-05 | 2021-11-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法 |
| WO2017070423A1 (en) | 2015-10-22 | 2017-04-27 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| MX2018009633A (es) | 2016-02-09 | 2018-12-17 | Inventisbio Inc | Inhibidor de indoleamina-2,3-dioxigenasa (ido). |
| JP7066186B2 (ja) | 2016-02-19 | 2022-05-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 肥満の処置のための方法及び医薬組成物 |
| RU2741911C2 (ru) * | 2016-04-29 | 2021-01-29 | Иомет Фарма Лтд. | Новые замещенные соединения имидазопиридина в качестве ингибиторов индоламин-2,3-диоксигеназы и/или триптофан-2,3-диоксигеназы |
| BR112018072669A2 (pt) * | 2016-05-12 | 2019-02-19 | Glaxosmithkline Intellectual Property Development Limited | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratamento uma doença ou condição que se beneficiaria da inibição de ido1, e, uso de um composto ou sal |
| AR108586A1 (es) | 2016-06-10 | 2018-09-05 | Lilly Co Eli | Compuestos de 2,3-dihidro-1h-indol |
| WO2018036414A1 (zh) * | 2016-08-23 | 2018-03-01 | 北京诺诚健华医药科技有限公司 | 稠杂环类衍生物、其制备方法及其在医学上的应用 |
| WO2018054365A1 (en) | 2016-09-24 | 2018-03-29 | Beigene, Ltd. | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES |
| MA46649A (fr) | 2016-10-13 | 2019-08-21 | Juno Therapeutics Inc | Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane |
| KR20190088480A (ko) | 2016-11-02 | 2019-07-26 | 조운스 테라퓨틱스, 인크. | Pd-1에 대한 항체 및 그의 용도 |
| CA3042698A1 (en) | 2016-11-04 | 2018-05-11 | Aximmune, Inc. | Beta-alethine, immune modulators, and uses thereof |
| EP3558978A1 (en) | 2016-12-20 | 2019-10-30 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| CN114989205A (zh) | 2016-12-22 | 2022-09-02 | 卡里塞拉生物科学股份公司 | 用于抑制精氨酸酶活性的组合物和方法 |
| CA3047002A1 (en) | 2017-01-17 | 2018-07-26 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| EP3694506B1 (en) | 2017-10-09 | 2023-08-02 | Merck Sharp & Dohme LLC | Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| CN109836356B (zh) * | 2017-11-24 | 2022-03-08 | 沈阳化工研究院有限公司 | 一种芳甲醚衍生物及其应用 |
| WO2019126514A2 (en) | 2017-12-22 | 2019-06-27 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
| EP3697423A4 (en) | 2018-01-05 | 2021-08-11 | Dicerna Pharmaceuticals, Inc. | REDUCED EXPRESSION OF BETA-CATENIN AND IDO TO POTENTIALIZE IMMUNOTHERAPY |
| US11447449B2 (en) * | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| JP2021523213A (ja) | 2018-05-14 | 2021-09-02 | ジャウンス セラピューティックス， インク．Ｊｏｕｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 癌を治療する方法 |
| EP3823604A4 (en) | 2018-07-17 | 2022-03-16 | Board of Regents, The University of Texas System | COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE |
| WO2020023356A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12059420B2 (en) | 2018-07-23 | 2024-08-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2020081905A1 (en) | 2018-10-18 | 2020-04-23 | Jounce Therapeutics, Inc | Methods for treating cancer |
| WO2020086802A1 (en) | 2018-10-24 | 2020-04-30 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| US20210355222A1 (en) | 2018-10-26 | 2021-11-18 | Jounce Therapeutics, Inc. | Methods of Treating Cancer |
| WO2020185739A1 (en) | 2019-03-11 | 2020-09-17 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
| WO2021091960A1 (en) | 2019-11-05 | 2021-05-14 | Jounce Therapeutics, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
| CN115135385B (zh) | 2019-11-12 | 2024-05-10 | 纳米医疗有限公司 | 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法 |
| WO2021102618A1 (en) | 2019-11-25 | 2021-06-03 | InventisBio Co., Ltd. | Novel salts of indoleamine 2,3-dioxygenase inhibitors |
| US20230089426A1 (en) | 2020-01-13 | 2023-03-23 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| CN111153846B (zh) * | 2020-01-17 | 2021-08-31 | 中国药科大学 | 吡咯类化合物、其制备方法和药物组合物与用途 |
| MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| MX2023010371A (es) | 2021-03-05 | 2024-02-12 | Univ Basel | Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb. |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447957A (en) * | 1994-06-02 | 1995-09-05 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
| JP4618845B2 (ja) * | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| AU2002222573A1 (en) * | 2000-12-05 | 2002-06-18 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
| US7312214B2 (en) | 2002-05-10 | 2007-12-25 | Bristol-Myers Squibb Company | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors |
| US7056925B2 (en) * | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
| US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| ES2340179T3 (es) * | 2004-05-12 | 2010-05-31 | Bristol-Myers Squibb Company | Antagonistas de urea del receptor p2y1 utiles en el tratamiento de afecciones tromboticas. |
| CA2575764A1 (en) * | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as cb1 antagonists |
| GB0613674D0 (en) * | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
| CN102083429B (zh) * | 2008-04-24 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| HRP20180971T1 (hr) | 2013-03-15 | 2018-08-10 | Bristol-Myers Squibb Company | Inhibitori indolamin 2,3-dioksigenaze (ido) |
-
2014
- 2014-03-12 HK HK16108593.6A patent/HK1220442A1/zh unknown
- 2014-03-12 WO PCT/US2014/023877 patent/WO2014150646A1/en not_active Ceased
- 2014-03-12 AU AU2014235816A patent/AU2014235816B2/en not_active Ceased
- 2014-03-12 JP JP2016501372A patent/JP6313415B2/ja active Active
- 2014-03-12 MX MX2015012056A patent/MX2015012056A/es unknown
- 2014-03-12 ES ES14714106T patent/ES2733546T3/es active Active
- 2014-03-12 BR BR112015022462A patent/BR112015022462A8/pt not_active Application Discontinuation
- 2014-03-12 SG SG11201506920QA patent/SG11201506920QA/en unknown
- 2014-03-12 MA MA38483A patent/MA38483A1/fr unknown
- 2014-03-12 US US14/775,976 patent/US9624188B2/en active Active
- 2014-03-12 CA CA2907178A patent/CA2907178A1/en not_active Abandoned
- 2014-03-12 CN CN201480028214.8A patent/CN105324362B/zh not_active Expired - Fee Related
- 2014-03-12 EA EA201591823A patent/EA028424B1/ru not_active IP Right Cessation
- 2014-03-12 KR KR1020157029305A patent/KR20150129010A/ko not_active Ceased
- 2014-03-12 EP EP14714106.3A patent/EP2970114B1/en active Active
- 2014-03-12 PE PE2015001950A patent/PE20151594A1/es not_active Application Discontinuation
-
2015
- 2015-09-08 IL IL241321A patent/IL241321A0/en unknown
- 2015-09-10 PH PH12015502028A patent/PH12015502028A1/en unknown
- 2015-09-14 ZA ZA2015/06796A patent/ZA201506796B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160060237A1 (en) | 2016-03-03 |
| KR20150129010A (ko) | 2015-11-18 |
| MX2015012056A (es) | 2015-12-16 |
| MA38483A1 (fr) | 2018-02-28 |
| WO2014150646A1 (en) | 2014-09-25 |
| BR112015022462A8 (pt) | 2019-11-26 |
| IL241321A0 (en) | 2015-11-30 |
| EP2970114A1 (en) | 2016-01-20 |
| ZA201506796B (en) | 2017-08-30 |
| CA2907178A1 (en) | 2014-09-25 |
| PE20151594A1 (es) | 2015-11-19 |
| PH12015502028A1 (en) | 2016-01-18 |
| BR112015022462A2 (pt) | 2017-07-18 |
| AU2014235816A1 (en) | 2015-11-05 |
| US9624188B2 (en) | 2017-04-18 |
| AU2014235816B2 (en) | 2018-05-17 |
| EA201591823A1 (ru) | 2016-01-29 |
| ES2733546T3 (es) | 2019-11-29 |
| CN105324362B (zh) | 2017-05-24 |
| SG11201506920QA (en) | 2015-09-29 |
| CN105324362A (zh) | 2016-02-10 |
| EP2970114B1 (en) | 2019-05-15 |
| HK1220442A1 (zh) | 2017-05-05 |
| EA028424B1 (ru) | 2017-11-30 |
| JP2016518324A (ja) | 2016-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6313415B2 (ja) | Ｉｄｏ阻害剤 | |
| JP6313416B2 (ja) | Ｉｄｏ阻害剤 | |
| JP6478991B2 (ja) | Ｉｄｏ阻害剤 | |
| ES2719327T3 (es) | Inhibidores de IDO | |
| JP6371851B2 (ja) | Ｉｄｏ阻害剤 | |
| CA2981657A1 (en) | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer | |
| EA027533B1 (ru) | Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps | |
| JP2018525341A (ja) | Ｉｄｏ阻害剤 | |
| WO2018028491A1 (zh) | 吲哚胺2，3-双加氧酶抑制剂及其在药学中的用途 | |
| CN121399101A (en) | TREK (TWIK related K)+Channel) inhibitors of channel function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170127 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171114 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180209 |
|
| TRDD | Decision of grant or rejection written | ||
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20180222 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180227 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180322 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6313415 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |